Dukes Iain D. 4

What Happened
Iain D. Dukes, CEO of Traws Pharma, received an award of 274,000 stock options (reported as a derivative grant) on July 9, 2026. The grant is reported at $0.00 per share (no immediate cash exchanged); the filing lists the transaction type as an award/grant (code A).

Key Details

• Transaction date: 2026-07-09; filing date (SEC accession): 2026-07-14. The filing was submitted five days after the reported transaction, which is later than the typical two-business-day Form 4 reporting window.
• Award size: 274,000 options; reported price: $0.00 (derivative award).
• Shares owned after the transaction: not specified in the filing.
• Footnote: The options were granted under the Issuer’s 2021 Incentive Compensation Plan and will vest 100% on the first anniversary of the grant date; award was approved by the compensation committee of independent directors.

Context
This was a grant of options (a compensation award), not an open-market purchase or sale. The options vest in one year; they have not been exercised or sold, so there was no immediate cash proceeds or share disposition reported. Grants are common as executive compensation and do not by themselves indicate the insider is buying or selling shares for personal investment.